Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis



Similar documents
Educational Session. Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan. Mechanisms of asbestos-induced carcinogenesis

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

International Symposium on Malignant Pleural Mesothelioma

Malignant Mesothelioma State of the Art

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Surgical therapy of. who should be operated

Mesothelioma Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

Malignant pleural mesothelioma P/D vs. EPP

THE NEWEST TRENDS IN LUNG CANCER & MESOTHELIOMA CASES

International Journal of Case Reports in Medicine

The New International Staging System Lung Cancer

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

SciRevision Japanese Clients/pro bono: Universities, Institutes, Companies (updated 1 November, 2007)

May 18, 2013 Sheraton Delfina Santa Monica, California

We look forward to both your participation and contribution to this meeting.

A Conference on Asbestos & Mesothelioma

Pleural Mesothelioma 2013:

May 18, 2013 Sheraton Delfina Santa Monica, California

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Courtney Broaddus University of California, San Francisco General Hospital, USA

Advances in Lung Cancer: A Multidisciplinary Approach

Occupational respiratory diseases due to Asbestos. Dirk Dahmann, IGF, Bochum

Malignant Mesothelioma: an Update

Report on New Patented Drugs - Alimta

The Features of World-Class Universities

May 21, 2011 Sheraton Delfina Santa Monica, California

Mesothelioma Applied Research Foundation

THE NEWEST TRENDS IN LUNG CANCER & MESOTHELIOMA CASES

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

Post-operative intrapleural chemotherapy for mesothelioma

A standardized technique of radical pleurectomy for mesothelioma that achieves a macroscopic complete resection, regardless of tumor bulk

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE

U.S. News Best Global Universities Rankings: An inside look at the latest results and methodology

Introduction to the. Mesothelioma Applied Research Foundation

Malignant pleural mesothelioma (MPM) is an uncommon

Lung Cancer & Mesothelioma

Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Master Online Study Oncology. Study part time team up internationally!

Report on the Committee on Assessment of the Health Effects of Fine Particulate Matter on Public Health

بسم هللا الرحمن الرحيم

Update on Clinical Trials and Foundation Funded Grants

A Career in Pediatric Hematology-Oncology? Think About It...

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April :10 14:20 Room C

FACULTY OF ALLIED HEALTH SCIENCES

Mesothelioma. Malignant Pleural Mesothelioma

Summary Report of Basic Survey on Wage Structure (starting salary)

UNIVERSITY TOP 50 BY SUBJECTS a) Arts and Humanities Universities

Globalization of Higher Education in Japan

Multi-disciplinary Thoracic Oncology:

Luis D. Carcorze Soto, MD PGY-3

Appendix 1 Current list of approved qualifications for Locum Tenens registration

How To Prevent Asbestos Related Diseases

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Exchange studies in Dentistry

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Update on Mesothelioma

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)

There must be an appropriate administrative structure for each residency program.

Dalhousie University 2014/2015 Enrolment Statistics - Enrolment by Faculty 1 and Field of Study as of December 1 (Headcounts) December 1, 2014

BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA

Results of Accreditations Performed by the Japan University Accreditation Association

National Framework for Excellence in

Plaintiffs Experts Latest Pathological Theories

Probe: Could you tell me about when?

Lessons learned from the Western Australian experience with mesothelioma

J of Evidence Based Med & Hlthcare, pissn , eissn / Vol. 2/Issue 33/Aug. 17, 2015 Page 5063

Elenco dei periodici elettronici in Ovid Full text

Targeted Therapy What the Surgeon Needs to Know

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Health effects of occupational exposure to asbestos dust

- Compensation issues

Asbestos-Related Cancer Research and Prevention

How To Prepare A Meeting For A Health Care Conference

Cancer and the immune system: can we beat cancer at its own game?

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

MESOTELIOMA and CHRYSOTILE

Influence of Fiber Type, Size, and Number in Human Disease: Conclusions from Fiber Burden Analysis

How To Treat Mesothelioma

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA

Exploring the Role of Vitamins in Achieving a Healthy Heart

Japanese Government s strategy on international education

Future Oncology: Technology, Products, Market and Service Opportunities

Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database

2016 Admissions Guide: Doctoral Program of Medicine. Graduate School of Medicine, the University of Tokyo

Page 1/.. USA / Canada - South Africa Schedule No. 4 / 2011-Jan-24

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany

Malignant Pleural Mesothelioma in Singapore

Life Insurance Fact Book (2014)

Announcement of Changes in Executive Personnel and Changes in Responsibilities of Executive Personnel (as of April 1, 2014)

Transcription:

Tuesday, Aug. 31 Room A Time: 8:00-8:10 Opening Remarks Time: 8:10-8:35 The mesothelial cell ES01 Time: 8:35-9:00 Educational Session Chair: Shotaro Maeda Tama-Nagayama Hospital, Nippon Medical School, Japan The mesothelial cell Steven Mutsaers Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Department of Medicine, University of Western Australia, Australia Mechanisms of asbestos-induced carcinogenesis ES02 Time: 9:00-9:25 Chair: Naohiko Inase Tokyo Medical and Dental University, Japan Mechanisms of asbestos-induced carcinogenesis Marie-Claude Jaurand INSERM, UMR U-674, IUH Université Paris Descartes, France Apoptosis and ES03 Time: 9:25-9:50 Chair: Hirotoshi Akita Hokkaido University Graduate School of Medicine, Japan Apoptosis and Courtney Broaddus University of California, San Francisco, Chief, Division of Pulmonary and Critical Care Medicine San Francisco General Hospital, USA New pathways for molecular targeted therapies ES04 Takashi Nakano, Conference Chair IMIG 2010 Hyogo College of Medicine, Japan Chair: Kazuhisa Takahashi Juntendo University School of Medicine, Japan New pathways for molecular targeted therapies Luciano Mutti Department of Medicine, Local Health Unit 11, Vercelli, Italy 21

Time: 9:50-10:15 Clinically relevant chromosomal and molecular biomarkers in asbestos-related tumors ES05 Time: 10:35-11:00 Chair: Yoshitaka Sekido Aichi Cancer Center, Hospital and Research Institute, Japan Clinically relevant chromosomal and molecular biomarkers in asbestos-related tumors Sakari Knuutila Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland Clinical aspects of malignant pleural ES06 Time: 11:00-11:25 Chair: Yoshirou Mochiduki National Hospital Organization Himeji Medical Center, Japan Clinical aspects of malignant pleural Hugo Schouwink Department of Pulmonary Diseases Medisch Spectrum Twente, Enschede, The Netherlands Peritoneal -Clinical and translational research in pharmacology of cancer chemotherapy- ES07 Time: 11:25-11:50 Chair: Eiji Shimizu Tottori University Faculty of Medicine, Japan Peritoneal Clinical and translational research in pharmacology of cancer chemotherapy Paul Sugarbaker Washington Cancer Institute, Washington, DC, USA Malignant Mesothelioma new diagnostic tools ES08 Time: 13:00-13:25 Chair: Hiroshi Niwa Seirei Mikatahara General Hospital, Japan Malignant new diagnostic tools Bruce Robinson National Centre for Asbestos Related Diseases, University of Western Australia, Australia Systemic therapy for : First and second-line treatment ES09 Chair: Mikio Oka Kawasaki Medical School, Japan Systemic therapy for : First and second-line treatment Hedy Kindler Section of Hematology/Oncology, University of Chicago, USA 22

Time: 13:25-13:50 Palliative benefit of chemotherapy for ES10 Time: 13:50-14:15 Chair: Yukito Ichinose National Kyushu Cancer Center, Japan Palliative benefit of chemotherapy for Jeremy Steele Department of Medical Oncology, St Bartholomew s Hospital, UK Immunotherapy for ES11 Time: 14:15-14:40 Chair: Yasuhiko Nishioka The University of Tokushima Graduate School, Japan Immunotherapy for Steven Albelda Thoracic Oncology Gene Therapy Program, University of Pennsylvania Medical Center, USA Gene therapy for ES12 Time: 15:00-15:25 Chair: Yoshinori Hasegawa Nagoya University Graduate School of Medicine, Japan Gene therapy for Daniel Sterman Thoracic Oncology Gene Therapy Program, University of Pennsylvania Medical Center, USA TNM staging of malignant pleural ES13 Time: 15:25-15:50 Chair: Shinichiro Miyoshi Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan TNM staging of malignant pleural Valerie Rusch Thoracic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, USA Role of radical surgery within a multimodality concept ES14 Chair: Hiroshi Date Graduate School of Medicine and Faculty of Medicine, Kyoto University, Japan Role of radical surgery within a multimodality concept Walter Weder Division of Thoracic Surgery, University Hospital Zürich, Switzerland 23

Time: 15:50-16:15 Overview of the surgical debate for pleural ES15 Time: 16:45-17:10 Chair: Masahiro Tsuboi Kanagawa Cancer Center, Japan Overview of the surgical debate for pleural Harvey Pass Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU Langone Medical Center and Cancer Center, USA Multimodality treatment of MPM ES16 Time: 17:10-17:35 Chair: Koichi Kaneko Saitama Medical University International Medical Center, Japan Multimodality treatment of MPM Paul Baas Department of Thoracic Oncology, The Netherlands Cancer Institute, The Netherlands European guidelines for the treatment of malignant pleural ES17 Time: 17:35-18:00 Chair: Meinoshin Okumura Osaka University Graduate School of Medicine, Japan European guidelines for the treatment of malignant pleural Jan van Meerbeeck Department of Respiratory Medicine and Thoracic Oncology, Ghent University Hospital, Belgium Trends in incidence ES18 Chair: Jim tewaternaude Asbestos Relief Trust, South Africa and School of Public Health, University of Cape Town, South Africa Trends in incidence Ken Takahashi Department of Environmental Epidemiology, University of Occupational and Environmental Health, Japan 24

Room B1 Time: 13:00-13:40 Pathology Lecture-1 Advances in the pathology of malignant Chair: Yoshihiro Matsuno Hokkaido University Hospital, Japan ES PL01 Advances in the pathology of malignant Time: 13:40-14:20 Andrew Churg Department of Pathology, University of British Columbia, Canada Pathology Lecture-2 Cytological diagnosis for Chair: Françoise Galateau-Sallé University of Caen, France ES PL02 Cytological diagnosis for Time: 15:00-15:40 Toshiaki Kamei Division of Pathology, Yamaguchi Grand Medical Center, Japan Pathology Lecture-3 Verification of the consensus statement from the IMIG2006 Chair: Yuichi Ishikawa The Cancer Institute, Japanese Foundation for Cancer Research, Japan ES PL03 Verification of the consensus statement from IMIG 2006 Time: 15:40-16:20 Victor Roggli Department of Pathology, Duke University Medical Center, USA Pathology Lecture-4 Mesothelioma with special references to diagnostic accuracy Chair: Steven Mutsaers University of Western Australia, Australia ES PL04 Mesothelioma with special references to diagnostic accuracy Kouki Inai Division of Medical Intelligence and Informatics, Hiroshima University Graduate School of Biomedical Sciences, Japan 25